Copyright ©The Author(s) 2020.
World J Gastroenterol. Apr 28, 2020; 26(16): 1901-1911
Published online Apr 28, 2020. doi: 10.3748/wjg.v26.i16.1901
Figure 1
Figure 1 Microbiota-centered therapies against non-alcoholic fatty liver disease. Gut microbiota dysbiosis and impaired intestinal barrier have been elucidated as pathogenic factors in non-alcoholic fatty liver disease. Antibiotics, probiotics, prebiotics, synbiotics, fecal microbiota transplantation, and gut microbiota-derived components and metabolites are important treatments targeting the gut microbiota. FMT: Fecal microbiota transplantation.